Team:Munich/workspace/Annika

ALiVE

Analysis of Living Cells by Vesicular Export

Problems in Cell therapy

The Cell Status in Unknown

In modern day cell therapies like CAR - T cells the patients T - cells are isolated out of the body, modified in the laboratory and retranplanted into the patient. From this point on the cell´s status is largely unknown.

Why is this a Problem ?

Like with all other therapies, it is impoortant to know what your therapeutic device is doing. The cells can mutate, die or go rogue.

Until now in order to know the cell status, we need to isolate the cell of interest out of the patient and lyse the cell to analyze them. This means a one time measurement is all we can get.

Dropdown

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.

First Element:

Subtitle?

• 1
• 2
• 3

Second Element:

• 1
• 2

Third Element:

Stuff

• 1

Fourth Element

• 1
• 2

Fullscreen Pic

Half Half

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.

Different Background Box

ALiVE is online

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.

Our greatest glory is not in never falling, but in rising every time we fall.

Confucius

Video

Half Half Alt Background

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.

References

1. Centers for Disease Control and Prevention, 2017. Antibiotic/Antimicrobial Resistance.
2. ECDC Data and reports: Antimicrobial resistance and consumption, 2017
3. Liu, Y.-Y. et al. Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study. Lancet Infect. Dis. 16, 161–168 (2016).
4. Barriere, S. L. Clinical, economic and societal impact of antibiotic resistance. Expert Opin. Pharmacother. 16, 151–153 (2015).
5. Dierig, A., Frei, R. & Egli, A. The fast route to microbe identification: matrix assisted laser desorption/ionization-time of flight mass spectrometry (MALDI-TOF MS). Pediatr. Infect. Dis. J. 34, 97–9 (2015).
6. Ng, E. W. Y., Wong, M. Y. M. & Poon, T. C. W. in 139–175 (Springer, Berlin, Heidelberg, 2013).
7. Theriot, C. M. et al. Antibiotic-induced shifts in the mouse gut microbiome and metabolome increase susceptibility to Clostridium difficile infection. Nat. Commun. 5, 3114 (2014).
8. Międzybrodzki, R. et al. Clinical Aspects of Phage Therapy. Adv. Virus Res. 83, 73–121 (2012).
9. Henry, M., Lavigne, R. & Debarbieux, L. Predicting in vivo efficacy of therapeutic bacteriophages used to treat pulmonary infections. Antimicrob. Agents Chemother. 57, 5961–8 (2013).
10. Pirnay, J.-P. et al. The Magistral Phage. Viruses 10, 64 (2018).
11. Gill, J., & Hyman, P. (2010). Phage Choice, Isolation, and Preparation for Phage Therapy. Current Pharmaceutical Biotechnology, 11(1), 2–14.
12. Fortier, L.-C. & Sekulovic, O. Importance of prophages to evolution and virulence of bacterial pathogens. Virulence 4, 354–365 (2013).
13. Fauconnier, A. in 253–268 (Humana Press, New York, NY, 2018). doi:10.1007/978-1-4939-7395-8_19
14. Navarro-Garcia, F. Escherichia coli O104:H4 Pathogenesis: an Enteroaggregative E. coli/Shiga Toxin-Producing E. coli Explosive Cocktail of High Virulence. Microbiol. Spectr. 2, (2014).
15. Colom, J. et al. Microencapsulation with alginate/CaCO3: A strategy for improved phage therapy. Sci. Rep. 7, 41441 (2017).

---

---